Development of a methodology to quantify tamoxifen and endoxifen in breast cancer patients by micellar liquid chromatography and validation according to the ICH guidelines

Talanta ◽  
2011 ◽  
Vol 84 (2) ◽  
pp. 314-318 ◽  
Author(s):  
Enrique Ochoa Aranda ◽  
Josep Esteve-Romero ◽  
Maria Rambla-Alegre ◽  
Juan Peris-Vicente ◽  
Devasish Bose
2010 ◽  
Vol 397 (4) ◽  
pp. 1557-1561 ◽  
Author(s):  
Josep Esteve-Romero ◽  
Enrique Ochoa-Aranda ◽  
Devasish Bose ◽  
Maria Rambla-Alegre ◽  
Juan Peris-Vicente ◽  
...  

Author(s):  
Beate Beer ◽  
Sabine Plattner ◽  
Michael Hubalek ◽  
Anne Oberguggenberger ◽  
Monika Sztankay ◽  
...  

AbstractThe application of cytochrome P450 2D6 (CYP2D6) genotyping to allow a personalized treatment approach for breast cancer patients undergoing endocrine therapy has been repeatedly discussed. However, the actual clinical relevance of the CYP2D6 genotype in the endocrine treatment of breast cancer still remains to be elucidated. A major prerequisite for the successful and valid evaluation of the CYP2D6 genotype with regard to its pharmacokinetic and clinical relevance is the availability of a comprehensive, accurate and cost-effective CYP2D6 genotyping strategy. Herein we present a CYP2D6 genotyping assay employing polymerase chain reaction (PCR)-ion pair reversed-phase high-performance liquid chromatography-electrospray ionization time-of-flight mass spectrometry (ICEMS). The genotyping strategy involves the simultaneous amplification of nine variable regions within the CYP2D6 gene by a two-step PCR protocol and the direct analysis of the generated PCR amplicons by ICEMS. The nucleotide composition profiles generated by ICEMS enable the differentiation of 37 of the 80 reported CYP2D6 alleles. The assay was applied to type the CYP2D6 gene in 199 Austrian individuals including 106 breast cancer patients undergoing tamoxifen treatment. The developed method turned out to be a highly applicable, robust and cost-effective approach, enabling an economical CYP2D6 testing for large patient cohorts.


2001 ◽  
Vol 38 (2-3) ◽  
pp. 200-208 ◽  
Author(s):  
David P. Atencio ◽  
Christopher M. Iannuzzi ◽  
Sheryl Green ◽  
Richard G. Stock ◽  
Jonine L. Bernstein ◽  
...  

2016 ◽  
Vol 452 ◽  
pp. 18-26 ◽  
Author(s):  
Takahiro Takayama ◽  
Haruhito Tsutsui ◽  
Ippei Shimizu ◽  
Tatsuya Toyama ◽  
Nobuyasu Yoshimoto ◽  
...  

Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2831
Author(s):  
Jee Ah Kim ◽  
Rihwa Choi ◽  
Hojeong Won ◽  
Seonwoo Kim ◽  
Hee Jun Choi ◽  
...  

Numerous studies have shown that vitamins reduce the risk of cancers, but the relationship between serum vitamin levels and breast cancer is still controversial. In this study, we evaluated serum levels of vitamins in Korean patients with benign breast disease or breast cancer and investigated their associations with clinical and laboratory parameters. Concentrations of vitamin A, D, and E, together with homocysteine and methylmalonic acid as biomarkers of vitamin B12 deficiency, were measured by high-performance liquid chromatography (HPLC) or liquid chromatography with tandem mass spectrometry (LC-MS/MS) in the serum of 104 breast cancer patients, 62 benign breast disease patients, and 75 healthy Korean females. We further assessed possible associations between vitamin levels and breast cancer subtypes, the presence of lymph node metastasis, and tumor stages. Serum concentrations of vitamins A and E were significantly lower in breast cancer patients and in benign breast disease patients than in healthy controls. Severe vitamin D deficiency was more prevalent in breast cancer patients than in healthy controls. Vitamin D level was significantly lower in breast cancer patients with estrogen receptor-negative or triple-negative subtypes than in those with other subtypes. Further research with a larger study population is required to elucidate the role of vitamins in breast cancer.


Sign in / Sign up

Export Citation Format

Share Document